<p>強生（Johnson &amp; Johnson，NYSE:JNJ）的股價目標在週四的一份報告中被摩根士丹利的研究分析師從 167.00 美元上調至 169.00 美元，據 Benzinga 報道。該券商目前對該股票給予&#34;持平&#34;評級。摩根士丹利的股價目標指向股票當前價格的潛在上漲 7.93%。</p>
<p>獲取 <strong>強生（Johnson &amp; Johnson）</strong> 的警報：</p>
<ul>
<li>這家醫療巨頭的股票反彈：最低有 15% 的上漲空間</li>
</ul>
<p>其他幾家研究機構也對 JNJ 發表了評論。美國銀行在 4 月 17 日週三的一份研究報告中將強生（Johnson &amp; Johnson）的股價目標從 180.00 美元下調至 170.00 美元，併為該公司設定了&#34;中性&#34;評級。高盛集團在 5 月 30 日週四的一份研究報告中開始對強生（Johnson &amp; Johnson）進行覆蓋。他們給予了&#34;中性&#34;評級，併為該公司設定了 160.00 美元的目標價。加拿大皇家銀行在 6 月 17 日週一重申了對強生（Johnson &amp; Johnson）的&#34;跑贏市場&#34;評級，併為該公司設定了 175.00 美元的目標價。坎特菲茨傑拉德在 7 月 1 日週一的一份報告中重申了對強生（Johnson &amp; Johnson）的&#34;超配&#34;評級，併為該公司設定了 215.00 美元的目標價。最後，滙豐銀行在 4 月 18 日週四的一份研究報告中將強生（Johnson &amp; Johnson）的評級從&#34;持有&#34;調升至&#34;買入&#34;，並將股票的目標價從 169.00 美元上調至 170.00 美元。共有八位投資分析師對該股票進行了持有評級，五位給予了買入評級，一位對該公司進行了強烈買入評級。根據 MarketBeat.com 的數據，該股目前的共識評級為&#34;中等買入&#34;，共識目標價為 174.21 美元。</p>
<p><strong>查看我們對強生（Johnson &amp; Johnson）的最新股票報告</strong></p>
<h2>強生（Johnson &amp; Johnson）股價上漲 3.7%</h2>
<ul>
<li>MarketBeat 周評 - 7/8 - 7/12</li>
</ul>
<p>週四，JNJ 股票開盤價為 156.58 美元。該公司的 50 天移動平均價格為 148.15 美元，200 天移動平均價格為 153.39 美元。強生（Johnson &amp; Johnson）的 52 周最低價為 143.13 美元，52 周最高價為 175.97 美元。該公司的資產負債比為 0.36，速動比率為 0.94，流動比率為 1.17。該公司的市值為 3768.4 億美元，市盈率為 9.76，市盈增長比率為 2.54，貝塔係數為 0.52。</p>
<p>強生（Johnson &amp; Johnson，NYSE:JNJ）於 7 月 17 日週三公佈了其季度收益結果。該公司每股盈利為 2.82 美元，超過分析師預期的 2.71 美元，超出 0.11 美元。強生（Johnson &amp; Johnson）的淨利潤率為 45.26%，淨資產收益率為 36.70%。該公司在該季度實現了 224.5 億美元的收入，超過分析師對 223.3 億美元的預期。去年同期，該公司每股盈利為 2.80 美元。強生（Johnson &amp; Johnson）該季度的收入較去年同期增長了 4.3%。賣方分析師預計，強生（Johnson &amp; Johnson）本財年的每股盈利將達到 10.49 美元。</p>
<h2>對強生（Johnson &amp; Johnson）的對沖基金觀點</h2>
<ul>
<li>AbbVie 股票：投資者購買的絕佳時機</li>
</ul>
<p>一些對沖基金最近對 JNJ 的持倉進行了調整。挪威中央銀行在第四季度收購了約 4071.642 億美元的強生（Johnson &amp; Johnson）股份。惠靈頓管理集團在第四季度將其對強生（Johnson &amp; Johnson）的持股增加了 16.4%。惠靈頓管理集團現在擁有 2401.9725 萬股該公司股票，價值 3764.852 億美元，較上一季度增加了 339.1657 萬股。Price T Rowe Associates Inc. MD 在第一季度將其對強生（Johnson &amp; Johnson）的持股增加了 16.8%。Price T Rowe Associates Inc. MD 現在擁有 2183.4359 萬股該公司股票，價值 3453.978 億美元，較上一季度增加了 313.9499 萬股。瑞典銀行在第一季度收購了約 331.178 億美元的強生（Johnson &amp; Johnson）股份。最後，國際資產投資管理有限責任公司在第四季度將其對強生（Johnson &amp; Johnson）的持股增加了 7875.8%。國際資產投資管理有限責任公司現在擁有 209.0384 萬股該公司股票，價值 327.647 億美元，較上一季度增加了 206.4175 萬股。機構投資者和對沖基金擁有該公司股份的 69.55%。</p>
<h2>強生（Johnson &amp; Johnson）公司簡介（獲取免費報告）</h2>
<p>強生（Johnson &amp; Johnson）及其子公司在全球範圍內從事醫療保健領域的各種產品的研究、開發、製造和銷售。該公司的創新藥物部門提供各種治療領域的產品，包括免疫學，包括類風濕性關節炎、銀屑病性關節炎、炎症性腸病和牛皮癬；傳染病，包括 HIV/AIDS；神經科學，包括情緒障礙、神經退行性疾病和精神分裂症；腫瘤學，如前列腺癌、血液惡性腫瘤、肺癌和膀胱癌；心血管和代謝，包括血栓形成、糖尿病和黃斑變性；以及肺動脈高壓，通過零售商、批發商、分銷商、醫院和醫療保健專業人士供處方使用。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們喜歡的五隻股票比強生（Johnson &amp; Johnson）更好</li>
<li>如何找到被低估的股票</li>
<li>觀察這 4 只超買股票，隨着市場輪換的繼續</li>
<li>TSX 創業交易所（前身為加拿大創業交易所）</li>
<li>芯片股：廉價購買還是潛在崩盤？</li>
<li>股票中的死亡交叉是什麼？</li>
<li>黃金創新高：投資者應關注的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。在發佈之前，這則報道已經經過 MarketBeat 編輯團隊的審核。請將有關此報道的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ [緊急] 交易所利潤中的另類幣優選（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzU5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzU5"/></p>
<h2>現在是否值得投資$1,000 美元購買強生？</h2>
<p>在考慮是否投資強生之前，您需要聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票...而強生並不在名單上。</p>
<p>儘管強生目前在分析師中有一個&#34;持有&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

外服控股

強生

<p>摩根大通將強生的目標股價從 167 美元上調至 169 美元，並給予其"持平"評級。其他研究公司也對強生髮表了不同的評級意見。該股開盤價為 156.58 美元，52 周最高價為 175.97 美元。強生報告季度每股收益為 2.82 美元，超過了預期。對強生股票持有空頭頭寸的對沖基金已經調整了其持倉。該公司及其子公司在全球範圍內從事醫療保健產品的研究、開發、生產和銷售</p>

<p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) had its price target increased by research analysts at Morgan Stanley from $167.00 to $169.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an &#34;equal weight&#34; rating on the stock. Morgan Stanley's price target points to a potential upside of 7.93% from the stock's current price.</p>
<div class="lb-trans"><p>強生（Johnson &amp; Johnson，NYSE:JNJ）的股價目標在週四的一份報告中被摩根士丹利的研究分析師從 167.00 美元上調至 169.00 美元，據 Benzinga 報道。該券商目前對該股票給予&#34;持平&#34;評級。摩根士丹利的股價目標指向股票當前價格的潛在上漲 7.93%。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<ul>
<li>This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>強生（Johnson &amp; Johnson）</strong> 的警報：</p>
<ul>
<li>這家醫療巨頭的股票反彈：最低有 15% 的上漲空間</li>
</ul>
</div><p>Several other research firms have also commented on JNJ. Bank of America dropped their price objective on shares of Johnson &amp; Johnson from $180.00 to $170.00 and set a &#34;neutral&#34; rating for the company in a research note on Wednesday, April 17th. The Goldman Sachs Group assumed coverage on Johnson &amp; Johnson in a research report on Thursday, May 30th. They set a &#34;neutral&#34; rating and a $160.00 target price for the company. Royal Bank of Canada reiterated an &#34;outperform&#34; rating and issued a $175.00 target price on shares of Johnson &amp; Johnson in a report on Monday, June 17th. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating and issued a $215.00 target price on shares of Johnson &amp; Johnson in a report on Monday, July 1st. Finally, HSBC upgraded Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating and boosted their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $174.21.</p>
<div class="lb-trans"><p>其他幾家研究機構也對 JNJ 發表了評論。美國銀行在 4 月 17 日週三的一份研究報告中將強生（Johnson &amp; Johnson）的股價目標從 180.00 美元下調至 170.00 美元，併為該公司設定了&#34;中性&#34;評級。高盛集團在 5 月 30 日週四的一份研究報告中開始對強生（Johnson &amp; Johnson）進行覆蓋。他們給予了&#34;中性&#34;評級，併為該公司設定了 160.00 美元的目標價。加拿大皇家銀行在 6 月 17 日週一重申了對強生（Johnson &amp; Johnson）的&#34;跑贏市場&#34;評級，併為該公司設定了 175.00 美元的目標價。坎特菲茨傑拉德在 7 月 1 日週一的一份報告中重申了對強生（Johnson &amp; Johnson）的&#34;超配&#34;評級，併為該公司設定了 215.00 美元的目標價。最後，滙豐銀行在 4 月 18 日週四的一份研究報告中將強生（Johnson &amp; Johnson）的評級從&#34;持有&#34;調升至&#34;買入&#34;，並將股票的目標價從 169.00 美元上調至 170.00 美元。共有八位投資分析師對該股票進行了持有評級，五位給予了買入評級，一位對該公司進行了強烈買入評級。根據 MarketBeat.com 的數據，該股目前的共識評級為&#34;中等買入&#34;，共識目標價為 174.21 美元。</p>
</div><p><strong>View Our Latest Stock Report on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>查看我們對強生（Johnson &amp; Johnson）的最新股票報告</strong></p>
</div><h2>Johnson &amp; Johnson Trading Up 3.7 %</h2>
<ul>
<li>MarketBeat Week in Review – 7/8 - 7/12</li>
</ul>
<div class="lb-trans"><h2>強生（Johnson &amp; Johnson）股價上漲 3.7%</h2>
<ul>
<li>MarketBeat 周評 - 7/8 - 7/12</li>
</ul>
</div><p>JNJ stock opened at $156.58 on Thursday. The firm has a fifty day moving average price of $148.15 and a 200 day moving average price of $153.39. Johnson &amp; Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The firm has a market cap of $376.84 billion, a PE ratio of 9.76, a price-to-earnings-growth ratio of 2.54 and a beta of 0.52.</p>
<div class="lb-trans"><p>週四，JNJ 股票開盤價為 156.58 美元。該公司的 50 天移動平均價格為 148.15 美元，200 天移動平均價格為 153.39 美元。強生（Johnson &amp; Johnson）的 52 周最低價為 143.13 美元，52 周最高價為 175.97 美元。該公司的資產負債比為 0.36，速動比率為 0.94，流動比率為 1.17。該公司的市值為 3768.4 億美元，市盈率為 9.76，市盈增長比率為 2.54，貝塔係數為 0.52。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts' consensus estimates of $2.71 by $0.11. Johnson &amp; Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same period last year, the firm posted $2.80 earnings per share. Johnson &amp; Johnson's revenue for the quarter was up 4.3% compared to the same quarter last year. Sell-side analysts anticipate that Johnson &amp; Johnson will post 10.49 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>強生（Johnson &amp; Johnson，NYSE:JNJ）於 7 月 17 日週三公佈了其季度收益結果。該公司每股盈利為 2.82 美元，超過分析師預期的 2.71 美元，超出 0.11 美元。強生（Johnson &amp; Johnson）的淨利潤率為 45.26%，淨資產收益率為 36.70%。該公司在該季度實現了 224.5 億美元的收入，超過分析師對 223.3 億美元的預期。去年同期，該公司每股盈利為 2.80 美元。強生（Johnson &amp; Johnson）該季度的收入較去年同期增長了 4.3%。賣方分析師預計，強生（Johnson &amp; Johnson）本財年的每股盈利將達到 10.49 美元。</p>
</div><h2>Hedge Funds Weigh In On Johnson &amp; Johnson</h2>
<ul>
<li>AbbVie Stock: A Perfect Dip for Investors to Buy</li>
</ul>
<div class="lb-trans"><h2>對強生（Johnson &amp; Johnson）的對沖基金觀點</h2>
<ul>
<li>AbbVie 股票：投資者購買的絕佳時機</li>
</ul>
</div><p>A number of hedge funds have recently made changes to their positions in JNJ. Norges Bank acquired a new stake in shares of Johnson &amp; Johnson in the fourth quarter worth approximately $4,071,642,000. Wellington Management Group LLP boosted its stake in shares of Johnson &amp; Johnson by 16.4% in the fourth quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company's stock worth $3,764,852,000 after acquiring an additional 3,391,657 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Johnson &amp; Johnson by 16.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company's stock worth $3,453,978,000 after acquiring an additional 3,139,499 shares during the last quarter. Swedbank AB acquired a new stake in shares of Johnson &amp; Johnson in the first quarter worth approximately $331,178,000. Finally, International Assets Investment Management LLC grew its holdings in Johnson &amp; Johnson by 7,875.8% in the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company's stock valued at $327,647,000 after buying an additional 2,064,175 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近對 JNJ 的持倉進行了調整。挪威中央銀行在第四季度收購了約 4071.642 億美元的強生（Johnson &amp; Johnson）股份。惠靈頓管理集團在第四季度將其對強生（Johnson &amp; Johnson）的持股增加了 16.4%。惠靈頓管理集團現在擁有 2401.9725 萬股該公司股票，價值 3764.852 億美元，較上一季度增加了 339.1657 萬股。Price T Rowe Associates Inc. MD 在第一季度將其對強生（Johnson &amp; Johnson）的持股增加了 16.8%。Price T Rowe Associates Inc. MD 現在擁有 2183.4359 萬股該公司股票，價值 3453.978 億美元，較上一季度增加了 313.9499 萬股。瑞典銀行在第一季度收購了約 331.178 億美元的強生（Johnson &amp; Johnson）股份。最後，國際資產投資管理有限責任公司在第四季度將其對強生（Johnson &amp; Johnson）的持股增加了 7875.8%。國際資產投資管理有限責任公司現在擁有 209.0384 萬股該公司股票，價值 327.647 億美元，較上一季度增加了 206.4175 萬股。機構投資者和對沖基金擁有該公司股份的 69.55%。</p>
</div><h2>Johnson &amp; Johnson Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>強生（Johnson &amp; Johnson）公司簡介（獲取免費報告）</h2>
</div><p>Johnson &amp; Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.</p>
<div class="lb-trans"><p>強生（Johnson &amp; Johnson）及其子公司在全球範圍內從事醫療保健領域的各種產品的研究、開發、製造和銷售。該公司的創新藥物部門提供各種治療領域的產品，包括免疫學，包括類風濕性關節炎、銀屑病性關節炎、炎症性腸病和牛皮癬；傳染病，包括 HIV/AIDS；神經科學，包括情緒障礙、神經退行性疾病和精神分裂症；腫瘤學，如前列腺癌、血液惡性腫瘤、肺癌和膀胱癌；心血管和代謝，包括血栓形成、糖尿病和黃斑變性；以及肺動脈高壓，通過零售商、批發商、分銷商、醫院和醫療保健專業人士供處方使用。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>How to Find Undervalued Stocks</li>
<li>Watch These 4 Overbought Stocks As Market Rotation Continues</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>Chip Stocks: Bargain Buys or Looming Bust?</li>
<li>What is a Death Cross in Stocks?</li>
<li>Gold Hits New High: 3 Stocks Investors Should Watch</li>
</ul>
<div class="lb-trans"><h2>進一步閲讀</h2>
<ul>
<li>我們喜歡的五隻股票比強生（Johnson &amp; Johnson）更好</li>
<li>如何找到被低估的股票</li>
<li>觀察這 4 只超買股票，隨着市場輪換的繼續</li>
<li>TSX 創業交易所（前身為加拿大創業交易所）</li>
<li>芯片股：廉價購買還是潛在崩盤？</li>
<li>股票中的死亡交叉是什麼？</li>
<li>黃金創新高：投資者應關注的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。在發佈之前，這則報道已經經過 MarketBeat 編輯團隊的審核。請將有關此報道的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ [URGENT] Altcoin Winning Picks (From Crypto Swap Profits)(Ad)</p>
<div class="lb-trans"><p>→ [緊急] 交易所利潤中的另類幣優選（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzU5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8759&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Johnson &amp; Johnson right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 美元購買強生？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮是否投資強生之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票...而強生並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管強生目前在分析師中有一個&#34;持有&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

摩根士丹利將強生（NYSE:JNJ）的目標價上調至 169.00 美元